Engineers Gate Manager LP Increases Stock Position in Zoetis Inc. $ZTS

Engineers Gate Manager LP lifted its stake in Zoetis Inc. (NYSE:ZTS) by 3,551.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 107,678 shares of the company’s stock after acquiring an additional 104,729 shares during the quarter. Engineers Gate Manager LP’s holdings in Zoetis were worth $7,738,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in ZTS. California State Teachers Retirement System boosted its holdings in Zoetis by 6,680.3% in the second quarter. California State Teachers Retirement System now owns 47,745,365 shares of the company’s stock worth $3,430,982,000 after purchasing an additional 47,041,186 shares during the last quarter. BlackRock Inc. raised its stake in Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after buying an additional 3,845,869 shares during the last quarter. J. Stern & Co. LLP raised its stake in Zoetis by 12,431.2% during the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after buying an additional 23,877,416 shares during the last quarter. State Street Corp lifted its holdings in shares of Zoetis by 0.8% during the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock valued at $2,490,845,000 after buying an additional 149,382 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Zoetis by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock valued at $1,420,294,000 after buying an additional 189,235 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently commented on ZTS shares. Piper Sandler cut their price objective on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, August 10th. Barclays lowered their target price on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. Zacks Research cut Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. William Blair restated a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. Finally, Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Zoetis has an average rating of “Hold” and a consensus price target of $101.08.

Zoetis Trading Down 0.4%

NYSE:ZTS opened at $73.00 on Friday. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The firm has a market capitalization of $30.16 billion, a price-to-earnings ratio of 12.03, a price-to-earnings-growth ratio of 1.71 and a beta of 0.73. Zoetis Inc. has a one year low of $71.00 and a one year high of $152.00. The business has a fifty day moving average price of $75.60 and a 200-day moving average price of $92.10.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same period in the previous year, the business earned $1.76 earnings per share. Zoetis’s quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.2 EPS for the current year.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company’s product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.